Rimas V Lukas

List of Publications by Year
in descending order

106	2,749	236925 25	206112 48
papers	citations	h-index	g-index

113	113	113	4260
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nature Medicine, 2019, 25, 462-469.	30.7	569
2	Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Science Translational Medicine, 2019, 11, .	12.4	170
3	IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. Clinical Cancer Research, 2018, 24, 2559-2573.	7.0	147
4	A first-in-human phase 0 clinical study of RNA interferenceâ€“based spherical nucleic acids in patients with recurrent glioblastoma. Science Translational Medicine, 2021, 13, .	12.4	136
5	Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. Lung Cancer, 2019, 128, 105-112.	2.0	126
6	Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. Journal of Neuro-Oncology, 2018, 140, 317-328.	2.9	107
7	Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. Lancet Oncology, The, 2021, 22, 1103-1114.	10.7	91
8	The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma. Frontiers in Pharmacology, 2019, 10, 200.	3.5	82
9	Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. Epilepsy and Behavior, 2018, 80, 331-336.	1.7	78
10	Anti-N-methyl-D-aspartate-receptor encephalitis: diagnosis, optimal management, and challenges. Therapeutics and Clinical Risk Management, 2014, 10, 517.	2.0	63
11	The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy. Journal of Clinical Neuroscience, 2015, 22, 1964-1968.	1.5	61
12	Pleomorphic xanthoastrocytoma: a brief review. CNS Oncology, 2019, 8, CNS39.	3.0	53
13	Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clinical Cancer Research, 2020, 26, 5232-5245.	7.0	52
14	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology, 2019, 21, 1498-1508.	1.2	49
15	Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. Neuro-Oncology, 2020, 22, 470-479.	1.2	49
16	Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma. Clinical Cancer Research, 2021, 27, 6514-6528.	7.0	48
17	State-of-the-art considerations in small cell lung cancer brain metastases. Oncotarget, 2017, 8, 71223-71233.	1.8	47
18	Treatment of leptomeningeal carcinomatosis: Current challenges and future opportunities. Journal of Clinical Neuroscience, 2015, 22, 632-637.	1.5	46

#	Article	IF	Citations
19	Newly Diagnosed Glioblastoma: A Review on Clinical Management. Oncology, 2019, 33, 91-100.	0.5	42
20	Management of glioblastoma in elderly patients. Journal of the Neurological Sciences, 2017, 380, 250-255.	0.6	40
21	ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nature Cancer, 2021, 2, 1372-1386.	13.2	39
22	Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice. Journal of Neuro-Oncology, 2020, 148, 489-500.	2.9	38
23	Structure of neuroscience clerkships in medical schools and matching in neuromedicine. Neurology, 2015, 85, 172-176.	1.1	36
24	Leptomeningeal metastasis from solid tumors. Journal of the Neurological Sciences, 2020, 411, 116706.	0.6	34
25	Paraneoplastic epilepsy. Epilepsy and Behavior, 2016, 61, 51-58.	1.7	31
26	Glioblastoma as an age-related neurological disorder in adults. Neuro-Oncology Advances, 2021, 3, vdab125.	0.7	30
27	Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system. Neuro-Oncology, 2018, 20, 1197-1206.	1.2	27
28	Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod. Journal of Neuro-Oncology, 2019, 141, 111-120.	2.9	24
29	Student assessment by objective structured examination in a neurology clerkship. Neurology, 2012, 79, 681-685.	1.1	23
30	The interplay among psychological distress, the immune system, and brain tumor patient outcomes. Current Opinion in Behavioral Sciences, 2019, 28, 44-50.	3.9	22
31	Treatment of Brain Metastases. Oncology, 2014, 87, 321-329.	1.9	20
32	Skin toxicities associated with tumor treating fields: case based review. Journal of Neuro-Oncology, 2017, 135, 593-599.	2.9	19
33	Attitudes Toward Neurosciences in Medical Students in Wuhan, China: A Survey Study. World Neurosurgery, 2014, 82, 266-269.	1.3	17
34	Why neurology? Factors which influence career choice in neurology. Neurological Research, 2016, 38, 10-14.	1.3	17
35	Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice. Neuro-Oncology Practice, 2017, 4, 209-219.	1.6	17
36	Emerging therapies for malignant glioma. Expert Review of Anticancer Therapy, 2007, 7, S29-S36.	2.4	13

#	Article	IF	Citations
37	Tumor Treating Fields in Neuro-Oncological Practice. Current Oncology Reports, 2017, 19, 53.	4.0	13
38	Leptomeningeal metastases: the future is now. Journal of Neuro-Oncology, 2022, 156, 443-452.	2.9	11
39	Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus. Case Reports in Clinical Pathology, 2014, 1, 151-154.	0.0	10
40	Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. Future Oncology, 2016, 12, 1045-1058.	2.4	10
41	Immunotherapy Against Gliomas: is the Breakthrough Near?. Drugs, 2019, 79, 1839-1848.	10.9	10
42	Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma?. Journal of Neurosurgery, 2020, 132, 1667-1672.	1.6	10
43	Update in the Treatment of High-grade Gliomas. Neurologic Clinics, 2013, 31, 847-867.	1.8	9
44	Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches. CNS Oncology, 2014, 3, 61-75.	3.0	9
45	BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma. CNS Oncology, 2018, 7, CNS10.	3.0	9
46	Long-term outcomes of spinal ependymomas: an institutional experience of more than 60 cases. Journal of Neuro-Oncology, 2021, 151, 241-247.	2.9	9
47	Leptomeningeal carcinomatosis from breast cancer treated with intrathecal topotecan with concomitant intravenous eribulin. Journal of Clinical Neuroscience, 2014, 21, 1250-1251.	1.5	8
48	Hemangioblastoma diagnosis and surveillance in von Hippelâ€“Lindau disease: a consensus statement. Journal of Neurosurgery, 2022, 136, 1511-1516.	1.6	8
49	Case Report of Bone Marrow-Sparing Proton Therapy Craniospinal Irradiation for Central Nervous System Myelomatosis. Cureus, 2017, 9, e1885.	0.5	8
50	IMCT-21UPDATES ON PHASE 1B/2 COMBINATION STUDY OF THE IDO PATHWAY IHIBITOR INDOXIMOD WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH TEMOZOLOMIDE-REFRACTORY PRIMARY MALIGNANT BRAIN TUMORS. Neuro-Oncology, 2015, 17, v112.2-v112.	1.2	7
51	Impact of treatment variability on survival in immunoâ€competent and immunoâ€compromised patients with primary central nervous lymphoma. British Journal of Haematology, 2017, 177, 72-79.	2.5	7
52	Neurooncology Research in Nigeria: Great Untapped Potential. World Neurosurgery, 2019, 124, 381-385.	1.3	7
53	Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases. Journal of Neurology Research, 2012, 2, 1-9.	0.5	7
54	Assessment of neurological clinical management reasoning in medical students. Journal of Clinical Neuroscience, 2014, 21, 919-922.	1.5	6

#	Article	IF	Citations
55	ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy. Journal of Clinical Neuroscience, 2015, 22, 1978-1979.	1.5	6
56	Breadth versus volume: Neurology outpatient clinic cases in medical education. Journal of Clinical Neuroscience, 2016, 28, 20-23.	1.5	6
57	CNS hemangioblastomatosis in a patient without von Hippelâ€“Lindau disease. CNS Oncology, 2017, 6, 101-105.	3.0	6
58	Diagnostic Evaluation in Primary CNS Lymphoma. Neurologist, 2018, 23, 53-54.	0.7	6
59	Is Next-Generation Sequencing Alone Sufficient to Reliably Diagnose Gliomas?. Journal of Neuropathology and Experimental Neurology, 2020, 79, 763-766.	1.7	6
60	Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma. Translational Cancer Research, 2018, 7, S510-S513.	1.0	6
61	Clinical neuro-oncology for the neurologist. Neurology: Clinical Practice, 2020, 10, 458-465.	1.6	5
62	Complete Bilateral Hippocampal Diffusion Restriction and Reversible Amnesia Following Opiate, Cocaine, and Benzodiazepine Abuse. Cureus, 2021, 13, e12651.	0.5	5
63	Teaching Video Neuro Images : Myokymia and nerve hyperexcitability as components of Morvan syndrome due to malignant thymoma. Neurology, 2013, 80, e55.	1.1	4
64	Ambulatory training in neurology education. Journal of the Neurological Sciences, 2017, 372, 506-509.	0.6	4
65	Buzz Juice: Neurological sequelae of synthetic cannabinoids. Journal of Clinical Neuroscience, 2017, 37, 43.	1.5	4
66	Disappearance of MMR-deficient subclones after controlled IL-12 and PD-1 inhibition in a glioma patient. Neuro-Oncology Advances, 2021, 3, vdab045.	0.7	4
67	Clinical Neuro-Oncology Formal Education Opportunities for Medical Students in the United States and Canada. World Neurosurgery, 2014, 82, 938-944.	1.3	3
68	Newly diagnosed enhancing lesions: Steroid initiation may impede diagnosis of lymphoma involving the central nervous system. Journal of Clinical Neuroscience, 2020, 81, 61-64.	1.5	3
69	What is New in Neuro-oncology?. Neurologic Clinics, 2021, 39, 163-179.	1.8	3
70	Gene Therapy for the Treatment of Malignant Glioma. Advances in Oncology, 2021, 1, 189-202.	0.2	3
71	Leptomeningeal metastasesâ€”What outcomes should we measure and how?. Neuro-Oncology, 2022, 24, 1736-1737.	1.2	3
72	Hospital volume and group expertise in newly diagnosed glioblastoma management. Journal of Neuro-Oncology, 2018, 136, 213-214.	2.9	2

#	Article	IF	Citations
73	ATIM-15. A PHASE 1 STUDY OF Ad-RTS-hIL-12 + VELEDIMEX IN ADULTS WITH RECURRENT GLIOBLASTOMA: DOSE DETERMINATION WITH UPDATED OVERALL SURVIVAL. Neuro-Oncology, 2018, 20, vi3-vi4.	1.2	2
74	QOLP-25. QUALITY OF LIFE FOLLOWING RE-IRRADIATION FOR RECURRENT HIGH GRADE GLIOMA. Neuro-Oncology, 2018, 20, vi220-vi220.	1.2	2
75	Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage. Journal of Clinical Neuroscience, 2012, 19, 1310-1311.	1.5	1
76	Etoposide and Temozolomide in Combination for the Treatment of Progressive Small-Cell Lung Cancer Central Nervous System Metastases: Two Cases. Tumori, 2013, 99, e73-e76.	1.1	1
77	Society for Neuro-Oncology 2014 annual meeting updates on central nervous system metastases. Neuro-Oncology Practice, 2015, 2, 57-61.	1.6	1
78	Views on Careers in Clinical Neurosciences Among Neurosurgeons and Neurologists in China. World Neurosurgery, 2017, 98, 532-537.	1.3	1
79	Perceptions of clinical neurosciences among trainees in Wuhan, China. Future Neurology, 2017, 12, 65-70.	0.5	1
80	Delayed leptomeningeal metastasis of an adult anaplastic pilocytic astrocytoma. Brain Tumor Pathology, 2018, 35, 123-126.	1.7	1
81	QOLP-11. QUALITY OF LIFE IN HIGH-GRADE GLIOMA PATIENTS ON A PHASE I VIROTHERAPY STUDY. Neuro-Oncology, 2018, 20, vi216-vi216.	1.2	1
82			

#	Article	IF	Citations
91	IMMU-41. IDO1 INCREASES Treg RECRUITMENT INDEPENDENT OF TRYPTOPHAN METABOLISM IN A MODEL OF GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi130-vi130.	1.2	0
92	HOUT-10. SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI) TREATMENT IS ASSOCIATED WITH IMPROVED SURVIVAL AMONG ELDERLY PATIENTS DIAGNOSED WITH GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi115-vi115.	1.2	0
93	IMMU-46. GLIOBLASTOMA PATIENT DIAGNOSES AND IMMUNOSUPPRESSION ARE MAXIMAL DURING OLD AGE: A RANDOM COINCIDENCE, OR CAUSE AND EFFECT?. Neuro-Oncology, 2018, 20, vi131-vi131.	1.2	0
94	IMMU-35. PSYCHOSOCIAL STRESS NEGATIVELY IMPACTS IMMUNOTHERAPY IN IMMUNOCOMPETENT MODELS OF GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi128-vi129.	1.2	0
95	INNV-21. AN OVERVIEW OF NIGERIAN NEURO-ONCOLOGY SCHOLARLY OUTPUT. Neuro-Oncology, 2018, 20, vi142-vi142.	1.2	0
96	IMMU-10. RADIOTHERAPY AND PD-1 BLOCKADE INCREASES TRYPTOPHAN METABOLISM IN BRAIN TUMOR-DRAINING SECONDARY LYMPHOID ORGANS. Neuro-Oncology, 2018, 20, vi123-vi123.	1.2	0
97	Acute Neurological Complications of Brain Tumors and Immune Therapies, a Guideline for the Neuro-hospitalist. Current Neurology and Neuroscience Reports, 2020, 20, 32.	4.2	0
98	Commentary: Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons. Neurosurgery, 2020, 87, E289-E290.	1.1	0
99	Commentary: Long-Term Outcomes of Intra-Arterial Chemotherapy for Progressive or Unresectable Pilocytic Astrocytomas: Case Studies. Neurosurgery, 2021, 88, E343-E344.	1.1	0
100	â€œEstablishment of an acute headache infusion clinic as an alternative for emergency department careâ€• Journal of the Neurological Sciences, 2021, 423, 117384.	0.6	0
101	The Spinal Dural Arteriovenous Fistula in a Patient With Metastatic Renal Cell Carcinoma. Cureus, 2021, 13, e15303.	0.5	0
102	Tumor type, epilepsy burden, and seizure documentation: experiences at a single center neuro-oncology clinic. Neuro-Oncology Practice, 2021, 8, 581-588.	1.6	0
103	Introduction to the evolving landscape of the management of glioblastoma. Chinese Clinical Oncology, 2021, 10, 34-34.	1.2	0
104	An international perspective on the management of glioblastoma. Chinese Clinical Oncology, 2021, 10, 40-40.	1.2	0
105	American Society of Clinical Oncology 2021 Annual Meeting updates on primary brain tumors and CNS metastatic tumors. Future Oncology, 2021, 17, 4425-4429.	2.4	0
106	Multicenter Analysis Of Primary Central Nervous System Lymphoma: Patient Characteristics, Treatment Patterns and Survival. Blood, 2013, 122, 1803-1803.	1.4	0